153 related articles for article (PubMed ID: 29281685)
21. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting.
Li FQ; Su H; Wang J; Liu JY; Zhu QG; Fei YB; Pan YH; Hu JH
Int J Pharm; 2008 Feb; 349(1-2):274-82. PubMed ID: 17870261
[TBL] [Abstract][Full Text] [Related]
22. A simple improved desolvation method for the rapid preparation of albumin nanoparticles.
Jahanban-Esfahlan A; Dastmalchi S; Davaran S
Int J Biol Macromol; 2016 Oct; 91():703-9. PubMed ID: 27177461
[TBL] [Abstract][Full Text] [Related]
23. Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
Langer K; Balthasar S; Vogel V; Dinauer N; von Briesen H; Schubert D
Int J Pharm; 2003 May; 257(1-2):169-80. PubMed ID: 12711172
[TBL] [Abstract][Full Text] [Related]
24. Chitosan nanoparticle as protein delivery carrier--systematic examination of fabrication conditions for efficient loading and release.
Gan Q; Wang T
Colloids Surf B Biointerfaces; 2007 Sep; 59(1):24-34. PubMed ID: 17555948
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA.
Abiri N; Pang J; Ou J; Shi B; Wang X; Zhang S; Sun Y; Yang D
PLoS One; 2018; 13(3):e0193339. PubMed ID: 29513721
[TBL] [Abstract][Full Text] [Related]
26. Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Lee HJ; Park HH; Kim JA; Park JH; Ryu J; Choi J; Lee J; Rhee WJ; Park TH
Biomaterials; 2014 Feb; 35(5):1696-704. PubMed ID: 24262100
[TBL] [Abstract][Full Text] [Related]
27. Elucidation of structural and functional properties of albumin bound to gold nanoparticles.
Mariam J; Sivakami S; Dongre PM
J Biomol Struct Dyn; 2017 Feb; 35(2):368-379. PubMed ID: 26821333
[TBL] [Abstract][Full Text] [Related]
28. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation.
Wacker M; Zensi A; Kufleitner J; Ruff A; Schütz J; Stockburger T; Marstaller T; Vogel V
Int J Pharm; 2011 Jul; 414(1-2):225-32. PubMed ID: 21571055
[TBL] [Abstract][Full Text] [Related]
29. Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.
Anguizola J; Debolt E; Suresh D; Hage DS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():175-181. PubMed ID: 26468085
[TBL] [Abstract][Full Text] [Related]
30. Using bound fatty acids to disclose the functional structure of serum albumin.
Reichenwallner J; Hinderberger D
Biochim Biophys Acta; 2013 Dec; 1830(12):5382-93. PubMed ID: 23643928
[TBL] [Abstract][Full Text] [Related]
31. α-Lactalbumin nanoparticles prepared by desolvation and cross-linking: structure and stability of the assembled protein.
Arroyo-Maya IJ; Hernández-Sánchez H; Jiménez-Cruz E; Camarillo-Cadena M; Hernández-Arana A
Biophys Chem; 2014; 193-194():27-34. PubMed ID: 25105879
[TBL] [Abstract][Full Text] [Related]
32. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.
Fahrländer E; Schelhaas S; Jacobs AH; Langer K
Nanotechnology; 2015 Apr; 26(14):145103. PubMed ID: 25789544
[TBL] [Abstract][Full Text] [Related]
33. The influence of fatty acids on determination of human serum albumin thiol group.
Jovanović VB; Pavićević ID; Takić MM; Penezić-Romanjuk AZ; Aćimović JM; Mandić LM
Anal Biochem; 2014 Mar; 448():50-7. PubMed ID: 24316317
[TBL] [Abstract][Full Text] [Related]
34. Heterocoagulation as a facile route to prepare stable serum albumin-nanoparticle conjugates for biomedical applications: synthetic protocols and mechanistic insights.
Au KM; Armes SP
ACS Nano; 2012 Sep; 6(9):8261-79. PubMed ID: 22913736
[TBL] [Abstract][Full Text] [Related]
35. Isolation of esterified fatty acids bound to serum albumin purified from human plasma and characterised by MALDI mass spectrometry.
Belgacem O; Stübiger G; Allmaier G; Buchacher A; Pock K
Biologicals; 2007 Mar; 35(1):43-9. PubMed ID: 16580227
[TBL] [Abstract][Full Text] [Related]
36. [Study of the structure of human serum albumin, liberated from fatty acids, by a tritium marker method].
Dzhafarov ES
Mol Biol (Mosk); 1992; 26(1):168-72. PubMed ID: 1508166
[TBL] [Abstract][Full Text] [Related]
37. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method.
Lin W; Coombes AG; Davies MC; Davis SS; Illum L
J Drug Target; 1993; 1(3):237-43. PubMed ID: 8069565
[TBL] [Abstract][Full Text] [Related]
38. Vortex Fluidic Mediated Synthesis of Macroporous Bovine Serum Albumin-Based Microspheres.
Luo X; Al-Antaki AHM; Harvey DP; Ruan Y; He S; Zhang W; Raston CL
ACS Appl Mater Interfaces; 2018 Aug; 10(32):27224-27232. PubMed ID: 30028117
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns).
Erukula SV; Srivari Y; Chatterjee P
J Microencapsul; 2016 Sep; 33(6):524-534. PubMed ID: 27549905
[TBL] [Abstract][Full Text] [Related]
40. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting.
Gong G; Zhi F; Wang K; Tang X; Yuan A; Zhao L; Ding D; Hu Y
Nanotechnology; 2011 Jul; 22(29):295603. PubMed ID: 21673386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
